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Background: Iron deficiency anaemia and oral iron supplementation have been associated negatively with quality
of life, and with adverse effects, respectively, in subjects with inflammatory bowel disease (IBD). Hence, the
risk-benefit ratio of oral iron is not understood in this patient group. The present case–control study investigated
whether dietary iron intake impacts on quality of life in IBD patients.
Methods: Quality of life, habitual dietary iron intakes and iron requirements were assessed in 29 patients with
inactive or mildly active IBD as well as in 28 healthy control subjects.
Results: As expected, quality of life was worse in IBD patients as a whole in comparison to healthy controls
according to EuroQol score and EuroQol VAS percentage (6.9 ± 1.6 vs 5.3 ± 0.6; p< 0.0001 and 77 ± 14% vs 88 ±
12%; p=0.004 respectively). For IBD subjects, 21/29 were iron deplete based upon serum iron responses to oral iron
but, overall, were non-anaemic with mean haemoglobin of 13.3 ± 1.5 g/dL, and there was no difference in their
quality of life compared to 8/29 iron replete subjects (Hb 14.0 ± 0.8 g/dL). Interestingly, total dietary iron intake was
significantly negatively associated with quality of life in IBD patients, specifically for non-haem iron and, more
specifically, for fortificant iron. Moreover, for total non-haem iron the negative association disappeared when
fortificant iron values were subtracted. Finally, further sub-analysis indicated that the negative association between
(fortificant) dietary iron intake and quality of life in IBD patients is driven by findings in patients with mildly active
disease rather than in patients with quiescent disease.
Conclusions: Iron deficiency per se (i.e. without concomitant anaemia) does not appear to further affect quality of
life in IBD patients with inactive or mildly active disease. However, in this preliminary study, dietary iron intake,
particularly fortificant iron, appears to be significantly negatively associated with quality of life in patients with
mildly active disease.
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Iron deficiency (ID) is common in patients with inflam-
matory bowel disease (IBD) (36-90% prevalence [1-3]),
and when this results in moderate or severe anaemia is
associated with sub-optimal quality of life [4,5]. Well-
being, mood, physical activity and social activities are
especially affected. Somewhat paradoxically there is* Correspondence: jonathan.powell@mrc-hnr.cam.ac.uk
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reproduction in any medium, provided the orconcern that supplementation with oral iron, in patients
with IBD, may also induce symptoms and impact quality
of life [6-10] probably due to the free-radical generating
activity of unabsorbed luminal iron and the detrimental
effect this has on an already sensitive mucosa [11].
Indeed, in animal models of IBD, this, and the under-
lying mechanisms, have been demonstrated as have the
knock-on sequelae in terms of colonic cancer risks
including with relatively low ‘fortificant’ levels of dietary
iron [12-16]. In short, therefore, the ‘risk-benefit ratio’
(i.e. balancing sub-optimal iron status with undesirableLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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iron intakes in patients with IBD is not known. To
address this issue we took advantage of a study investi-
gating iron intakes and absorption in IBD patients [17]
by additionally measuring quality of life. Unlike previous
work, our cohort excluded subjects with moderate or se-
vere anaemia. Nonetheless, such a study is not straight-
forward because in the absence of severe anaemia, the
diagnosis of iron deficiency using routine clinical mea-
sures is flawed in subjects with IBD mainly as a result of
chronic (including low grade, sub-chronic) inflammatory
processes [18]. However, by measuring iron absorption
in each subject we were able to separate subjects, accur-
ately, as those requiring iron (iron deplete) and those
not requiring iron (iron replete) and thus could compare
these stratifications with quality of life. The pros and
cons of this approach versus ‘conventional’ haematology
measures are carefully addressed elsewhere [17],
[Powell et al., 2012, submitted]. In addition, using an
iron-specific, validated, food frequency questionnaire
(FFQ) [19], we collected dietary data enabling us to in-
vestigate associations between dietary iron intakes and
quality of life in IBD patients.
Subjects and methods
Study design
Twenty nine IBD patients (5 with ulcerative colitis and
24 with Crohn’s disease) were recruited from gastro-
intestinal outpatient clinics at Guy’s and St Thomas’
NHS Hospital Trust (GSTT), London, UK. Control sub-
jects (n=28) were recruited from a local newspaper advert.
This study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all proce-
dures involving human subjects were approved by the St
Thomas’ Hospital Local Research Ethics Committee
(EC03/089). Written informed consent was obtained
from all subjects.
The data presented here were collected as part of a
wider programme and further details including iron sta-
tus, inflammatory status and absorption data have been
previously published [17]. Mild anaemia was defined
as a haemoglobin concentration of 11–12.9 g/dl
(male) and 10.5-12.0 g/dl (female) [18]. Subjects with
non-Fe-deficiency anaemia, moderate-severe disease ac-
tivity (e.g. Harvey Bradshaw Index [HBI] >8 [20]) or
homozygous mutations of the HFE gene were excluded
from the study.
Patients
Twenty nine patients, aged 18 to 65, were recruited from
outpatient gastroenterology clinics at GSTT and in
all cases IBD was diagnosed by histological and/or
radiological techniques. Five patients had ulcerative
colitis and 24 had Crohn’s disease. Patients with otherchronic diseases, hereditary disorders of iron metabolism
(detected by assessment of common mutations in the
HFE gene), pregnant or lactating females and those who
had received iron therapy within the previous 28 days
were excluded. Additionally, only patients with inactive
or mildly active disease, i.e. with an HBI in the range of
0–4 or in the range 5–8 respectively [20], were included
in the study as detailed elsewhere [17]. HBI is validated
for use with Crohn’s disease, as the large majority of
patients had here, but, as previously [17], its use was also
extended to the few ulcerative colitis patients for
consistency with all patient subject measures.Controls
An advert was placed in a freely available newspaper dis-
tributed predominantly within Greater London. Potential
subjects responding to the advert were screened by tele-
phone to exclude anyone with known chronic disease,
gastrointestinal disease, hereditary disorders of iron me-
tabolism and those taking proton-pump inhibitor medi-
cation or iron therapy/supplements within the previous
28 days. Pregnant and lactating women were also
excluded. Mutations of the HFE gene were later assessed
as before [17].Quality of life questionnaires
Two questionnaires were administered to assess quality
of life. Firstly, we used the EuroQol EQ-5D VAS,
designed to measure health related quality of life across
a wide range of health conditions. This was used on both
the IBD subjects and the controls. Secondly, the McMaster
Inflammatory Bowel Disease Questionnaire (IBDQ) was
used but, by definition, only for the IBD subjects.
The EQ-5D, developed by EuroQol, is self-administered
and takes less than five minutes to complete. It comprises
five dimensions of health: mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression. Each di-
mension has three levels: (1) no problems, (2) some/
moderate problems and (3) extreme problems. Each level
is allocated points: one point for no problems, two for
some/moderate and three for extreme. A score is calcu-
lated by adding together the points for each dimension.
The lowest possible score is five and the maximum 25. In
addition subjects were asked to complete a self-rated
health status on a visual analogue scale (VAS). This con-
sisted of a vertical graduated line that the subjects used to
indicate their health status on the day of the study. The
bottom of the line represented the worst possible health
state and the top the best imaginable health state. Subjects
indicated their health status on the scale by drawing a line
from a box labelled ‘Your own health state today’ to the ap-
propriate point on the scale. Thus, two measures, namely
EuroQol score and EuroQol VAS percentage were derived.
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questionnaire and has been extensively validated [21].
This questionnaire has been shown to be more sensitive
in detecting change in quality of life compared with a
generic questionnaire, thus indicating that it is disease
specific. The questionnaire has been shown to be a reli-
able indicator of change in disease activity for both
Crohn’s disease and ulcerative colitis [22]. The McMas-
ter IBDQ consists of 32 questions designed to assess
four different domains: (1) emotional function (2) bowel
function (3) social function and (4) systemic function.
Each question is scored on a seven point Likert scale.
The total score value ranges from 32 to 224 points and a
higher score indicates better health-related quality of life.
The questionnaire was self-administered.
Dietary iron intake
A specific FFQ was used to assess intakes of dietary iron
over the previous month. The FFQ was a validated com-
puterised quantitative food frequency questionnaire
developed specifically for iron, as well as its absorption
modifiers [19], although only iron, and not the absorp-
tion modifiers, was considered in this work. Fortificant
iron was calculated as follows: (i) for food products
which contain almost no other iron sources apart from
‘added’ iron, e.g. Fortisip drink, the iron content declared
by the manufacturer was taken as fortificant iron; (ii) for
food products which are fortified with iron to varying
levels at the discretion of the manufacturer, e.g. breakfast
cereals, the level of ‘natural’ (i.e. not added) non-haem
iron was estimated based on the ingredients information
using the McCance and Widdowson food composition
tables [23], and this value was then subtracted from the
total iron content declared by the manufacturer to esti-
mate fortificant iron content; and (iii) for other foods
containing white wheat flour, which is fortified with iron
as a requirement under the UK Bread and Flour Regula-
tion 1995, fortificant iron was estimated by considering
the content of white flour per food portion and using
the standard ‘restoration’ formula of 1.65 mg Fe/100 g
white flour to derive the content of fortificant iron perTable 1 FFQ food items containing a mixture of fortificant iro
sources (i.e. non-haem and/or haem iron)
Sponge cake Fruit cake
Stuffing, sage and onion Yorkshire p
Quiche, cheese and egg Croissants
Shortbread Lemon mer
Pizza, cheese and tomato Samosa, ve
Steak and kidney pie Chicken pie
Iced cakes, fancy Choux bun
Danish pastry Doughnuts
Custard tart Coconut cafood portion. Foods falling within this latter category, for
the FFQ used in this work, are shown in Table 1. Natural
non- haem iron (i.e. not-added, dietary-derived iron)
was calculated by subtracting fortificant iron from total
non-haem iron. All values for the different categories of
dietary iron were calculated as total daily intakes for
each subject.
Classification of iron status
Subjects were classified as iron deplete or replete based
on the serum iron curves obtained following the admin-
istration of a single 200 mg ferrous sulphate capsule
(equivalent to 65 mg elemental Fe). Methods and results
of this comparative absorption study have been recently
published [17]. Iron deplete were defined as having a rise
in serum iron greater than 5 μmol/L from baseline in a
four-hour period following ingestion of 65 mg of iron as
ferrous sulphate [17]. Iron replete had a serum iron rise
of less than 5 μmol/L over the same period of time [17].
This classification was used to predict iron requirements
as traditional clinical haematological parameters (ferritin,
transferrin saturation etc.) are not a reliable indicator of
iron status in IBD patients [17,18] and, apart from bone
marrow staining, iron absorption is the best measure of
iron requirements [21,24].
Statistical analysis
Comparisons between healthy controls and IBD patients
were made using unpaired t tests. Significance was
assumed at p ≤ 0.05. Values expressed are mean ± stand-
ard deviation. Significance of associations between the dif-
ferent fractions of dietary iron intake and quality of life
were assessed using simple linear regression (Pearson’s
product moment correlation coefficient ) and multiple li-
near regression (where appropriate).
Results
As expected, EuroQol score and EuroQol VAS percentage
were significantly different between IBD patients and
healthy control subjects (6.9 ± 1.6 vs 5.3 ± 0.6; p< 0.0001








, jam or custard Cream crackers
ke Brown bread
Figure 1 Association between quality of life measured with McMaster IBDQ with A) total dietary iron, B) non-haem iron, C) haem iron,
and D) fortificant iron in IBD patients: E) association between IBDQ score and dietary iron intake as per a) in relation to disease
activity. r, Pearson correlation coefficient; p, p-value for the slope deviation from zero.
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Figure 2 Association between quality of life measured with EuroQol VAS percentage with A) total dietary iron, B) non-haem iron, C)
haem iron and D) fortificant iron in IBD patients: E) association between EuroQol VAS percentage and dietary iron intake as per a) in
relation to disease activity. r, Pearson correlation coefficient; p, p-value for the slope deviation from zero.
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Figure 3 Association between quality of life measured with A)
McMaster IBDQ and B) EuroQol VAS percentage for ‘natural’
dietary non-haem iron in IBD patients. Natural non-haem iron
represents not-added, dietary-derived iron, calculated by subtracting
fortificant iron from total non-haem iron.
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patients that were iron deplete and iron replete. Twenty
one patients were classified as iron deplete (4/21 having
concomitant mild anaemia) and eight as iron replete
(none with concomitant anaemia). Respectively, there
were no significant differences in quality of life measured
using EuroQol score (7.0 ± 1.8 vs 6.6 ± 0.8; p=0.46),
EuroQol VAS percentage (79 ± 14% vs 75 ± 17%; p=0.56)
or McMaster IBDQ score (157 ± 36 vs 155 ± 15; p=0.84).
Interestingly, when looking at the association between
total dietary iron, non-haem iron, haem iron and fortifi-
cant iron intakes, against scores for quality of life in IBD
patients as measured by the McMaster IBDQ (Figure 1)
or the EuroQol VAS percentage (Figure 2), significant
negative associations were observed for total dietary
iron, non-haem iron and fortificant iron. Moreover, once
the fortificant iron values were removed (i.e. subtracted)
from non-haem iron intakes, to leave only ‘natural’ (nat-
urally dietary-derived) non-haem iron, the significant
negative association disappeared (Figure 3). Moreover,
there remained a significant negative association be-
tween fortificant iron and quality of life measured by ei-
ther IBDQ score (p=0.041) or EuroQol VAS percentage
(p=0.005) when using multiple linear regression and
considering fortificant iron, haem iron and ‘natural’ non-
haem iron as independent variables (predictors) and
quality of life as the dependent variable.
Finally, in dividing the IBD patient group into those
with quiescent disease (i.e. HBI 0–4) and those with
mildly active disease (i.e. HBI 5–8) it was clear that the
above associations were driven by findings in patients
with (mildly) active disease rather than in quiescence, al-
though the small subgroup numbers do not enable
robust statistical analysis (Figures 1E and 2E).
No associations were observed between the EuroQol
score and iron intakes (not shown), nor for control sub-
jects with any quality of life measure and iron intakes
(not shown).
Discussion
Studies have shown that increasing haemoglobin levels,
for those with moderate or severe anaemia, improves
quality of life in IBD patients [4,25,26] and therefore one
might expect iron status to reflect quality of life. However,
results from this small study show that, in the absence of
moderate or severe anaemia, there is no significant differ-
ence in quality of life between IBD patients classified as
iron deplete and iron replete. As noted previously, cat-
egorisation as iron replete/deplete is superior when based
upon oral iron challenge (as here) rather than standard
haematological parameters that can be disturbed in this
patient group [17,18,27]. The lack of observed difference
could be explained by the fact that, in this work, only 4/21
of the iron deplete patients had anaemia (which wasanyway mild) and, overall, the iron deplete group had a
mean haemoglobin level of 13.3 g/dL [17] (i.e. within the
normal reference range even if iron stores where low).
Similar work in patients with cancer showed the biggest
improvement in quality of life when haemoglobin levels
increased from 11 to 13 g/dL [28]. Therefore, the iron de-
plete patients in our study appear, in the main, have
haemoglobin levels above the threshold for the detection
of deterioration in quality of life. From this we can con-
clude that iron deficiency in the absence of anaemia does
not have a measurable effect on quality of life in IBD. This
is important information because there is evidence that
oral iron supplementation can have detrimental effects on
the symptoms of IBD [5,6,9,10,29,30], so only supplement-
ing when necessary seems prudent.
Moreover, for the IBD patients reported herein, we
found that their iron intakes, and in particular their
intakes of fortificant iron, were significantly negatively
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the McMaster IBDQ and EuroQol VAS percentage.
However, this association appears to ‘show up’ only in
patients with some degree of disease activity (Figures 1E
and 2E), although we accept that patient numbers were
low in these subgroups and a larger study would be
required to see if there really is no such association in
patients with quiescent disease.
Animal models have indicated that relatively small
changes to luminal iron in the colon can lead to exacerba-
tion of local inflammatory effects (and their biomarkers)
[12,13,15] and, similarly, that removal of luminal iron can
alleviate local inflammation [16]. However, the gastro-
intestinal effects of dietary/fortificant iron in humans with
IBD is not understood [31] and, so, these are the first data
to suggest that what is observed in animal models of IBD
may also be observed in the population with non-
quiescent IBD. Nevertheless, we recognise that the num-
bers studied here were small (n=29 overall and n=15 with
mildly active disease) and that the less sensitive measure
for quality of life in these subjects (i.e. the generic EuroQol
score) did not detect any association. Hence, the study
really needs repeating with a larger cohort, preferably lon-
gitudinally, but, if other findings are consistent, then this
would add further credibility to work suggesting that un-
absorbed dietary iron can have adverse effects in the colon
and especially in those with pre-existing inflammation.
If the above findings were verified, how might dietary
fortificant iron be mediating its effect in sensitive indivi-
duals? After all, compared to oral iron supplementation
(typically 60–120 mg Fe/day) the amount of iron in the
diet, even allowing for fortification, is low (5–25 mgFe/day
in this study) and whilst iron supplementation may be
problematic in some subjects with IBD [5,6,9,10,29,30] it
is clearly not to the extent that would be expected if diet-
ary iron alone were a problem. This is a puzzle that
deserves consideration although it is possible that there is
a low dose threshold for the iron effect or that long term
iron-effects are required (e.g. changes in colonic flora
[16]) that are not irreversibly experienced with the shorter
duration of supplementation. Finally, the chemical form of
the iron should be considered: for example, it is worth
noting that an inflammatory murine model of ulcerative
colitis showed that a mere doubling of dietary iron, using
iron EDTA, led to a 4–5 fold increase in tumour incidence
[32]. Even in the small study presented here, the range of
iron intakes was about four-fold.
To our knowledge the study presented herein is the
first study carried out in humans to investigate the im-
pact of dietary iron, particularly from iron-fortified pro-
ducts, on quality of life. We focused, especially, on IBD
patients as a potentially vulnerable and sensitive (to
effects) population. This study can be viewed as
hypothesis-generating and we propose that furtherstudies are undertaken to determine whether high diet-
ary iron intakes are, reproducibly, negatively associated
with quality of life in IBD patients (with or without ac-
tive disease) and, if so, firstly if this is related to en-
dogenous food-iron or fortificant iron (for the non-haem
fraction) and, secondly, if the issue extends to the wider
population in terms of dietary iron and long-term distal
gut health. In which case, for a healthy population with-
out pre-existing gut mucosal sensitivity, it is unlikely
that symptoms (quality of life) would be a sufficient indi-
cator and biochemical, microbial or histological para-
meters would be required.
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